(HealthDay News) — For healthy subjects, exogenous glucagon-like peptide 1 (GLP-1) attenuates hypoglycemia-induced acceleration of gastric emptying, according to a study published online March 5 in Diabetes Care.

Mark P. Plummer, MD, from the University of Adelaide in Australia, and colleagues examined whether GLP-1 attenuates hypoglycemia-induced acceleration of gastric emptying. Ten healthy subjects received intravenous GLP-1 or placebo during hypoglycemia and euglycemia. At time 0, subjects ingested beef mince labeled with 99mTc-sulfur-colloid and a marker of glucose absorption (3-O-methyl-glucose [OMG]). Gastric emptying was measured scintigraphically through 180 minutes and 3-OMG was sampled at 15-minute intervals.

The researchers found that gastric emptying and glucose absorption were accelerated during hypoglycemia (hypoglycemia/placebo versus euglycemia/placebo; P<0.001 and P<0.03, respectively). During euglycemia, GLP-1 slowed gastric emptying (euglycemia/placebo versus euglycemia/GLP-1; P<0.001). GLP-1 diminished hypoglycemia-induced acceleration of gastric emptying (hypoglycemia/placebo versus hypoglycemia/GLP-1; P<0.008) and glucose absorption (P<0.01).

“Acute administration of exogenous GLP-1 attenuates, but does not abolish, the acceleration of gastric emptying by insulin-induced hypoglycemia in healthy subjects,” the authors write.

Continue Reading

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)